Zim Laboratories Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Published 15 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹614 Cr

The company expects base business revenues in H2 FY '26 to be in line with last year's numbers, compensating for H1 shortfall. The company expects to achieve last year's revenue numbers in H2 FY '26, compensating for the shortfall in H1.

From Zim Laboratories Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹125

Market Cap

₹614 Cr

P/E Ratio

141.2

How does Zim Laboratories Ltd rank in Pharmaceuticals & Biotechnology?

Compare Zim Laboratories Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Zim Laboratories Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹105 Cr, net profit ₹4 Cr.

Full financials →

📊 Revenue & Sales Performance

→The company expects base business revenues in H2 FY '26 to be in line with last year's numbers, compensating for H1 shortfall.
→NIP (New Innovative Products) and OTF (Orally Thin Films) sales are anticipated to return to approx. INR 15–16 crores run rate in Q3 and Q4 FY '26.
→India and export order books remain strong, supporting revenue recovery in H2 FY '26 and beyond.
→New Marketing Authorizations (MAs) recently received—especially in ROW markets—are expected to commercialize within 3 to 6 months, driving growth.
→EU-GMP compliance and remediation expected by Q4 FY '26 will enable resumption of EU market sales starting Q1 or Q2 FY '27.
→Management targets 20–25% revenue growth and improved margins (14–15% EBITDA) in FY '27, assuming timely EU sales restart.
→Nutra segment demand expected to stabilize in Q3/Q4 FY '26 with institutional orders recovering.
→Working capital and inventory levels will rise proportionate to turnover growth.

📈 Profitability & Margins

→The company expects to achieve last year's revenue numbers in H2 FY '26, compensating for the shortfall in H1.
→Improvement in EBITDA expected in H2 FY '26 as 60% of sales ramp-up occurs, with gross contribution improving from 49.3% to 51%.
→EBITDA for FY '25 was INR44 crores; H2 FY '26 target around INR30 crores, indicating a recovery trajectory.
→FY '27 outlook is optimistic with expectations of 20%-25% revenue growth and EBITDA margins of around 14%-15%, contingent on successful EU-GMP certification and remediation.
→Margin improvement driven by product mix normalization, operational efficiencies, and resumption of innovative product sales starting from Q1 or Q2 FY '27.
→Capex largely completed with minor additional spends (~INR5 crores) for CAPA implementation, no significant borrowing increase expected.
→Working capital to increase proportionately with turnover; gearing ratios expected to remain stable.

See what Zim Laboratories Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

→The previously planned capex has been mostly completed.
→There is a marginal additional capex of around INR 5 crore related to CAPA implementation.
→Another INR 5 to 7 crore is planned for completion of balance capex, with borrowings already tied up.
→No significant further increase in borrowing or capex is expected beyond these amounts.
→The CAPA-related capex is approved by the Board.
→No mention of strategic investments beyond remedial and capex activities shared.

💰 Fundraising & Capital Structure

→The company has completed the planned capex, with only a marginal increase of around INR 5 crore related to CAPA implementation.
→Borrowings for the balance capex and CAPA have already been tied up; no further increase in borrowings or capex is planned.
→Term loan repayment has already started, and no new debt is anticipated.
→Working capital levels and debt gearing are stable, with no further debt increase expected.
→There is no mention of any new equity fundraising plans in the provided text.

See what Zim Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

→The company has a robust order book with orders already in hand, providing confidence for achieving year-end targets similar to the previous year.
→For innovative products like NIP and OTF, there was a shortfall in H1 due to audit-related prudence delaying order execution, but orders are moderating and expected to compensate in H2.
→Orders that were delayed in H1 for some customers are expected to come in H2, aiming to reach prior run rates of around INR 15-16 crores per quarter for NIP and OTF products.
→The business plan anticipates roughly 60% of annual business in H2, based on existing orders and expected government orders.
→The company has built inventory and secured orders for the second half to compensate for the shortfall in H1.
→Continued growth visibility exists due to marketing authorizations received, and new product commercialization timelines of 3-6 months post-approval.

Key Metrics

What Zim Laboratories's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Alivus Life Sciences Ltd (Q2 FY26)
Capex for H1 FY '26 was INR113 crores; Q2 alone INR61 crores. Key concall takeaways from Alivus Life's Q2 FY26 earnings call — and how it ranks against sector…
Solara Active (Q2 FY26)
Current facility capacity utilization is about 70%, with capacity available to serve new customers. Key concall takeaways from Solara Active's Q2 FY26 earnings…
Sun Pharma.Inds. (Q2 FY26)
India formulation sales grew 11% in Q2, outpacing Indian Pharmaceutical Market (IPM) growth mainly driven by volume and new product launches. Key concall…
Zydus Lifesciences Ltd (Q2 FY26)
Branded formulations in India growing ahead of market at 9% YoY, driven by chronic, cardiology, gynecology, and oncology therapies. Key concall takeaways from…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Zim Laboratories Ltd Q2 FY26 results?

What is Zim Laboratories Ltd share price analysis?

Zim Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 141.2 with a market cap of ₹614 Cr. Investors should review the full earnings analysis for detailed insights.

Is Zim Laboratories Ltd planning capital expenditure?

The previously planned capex has been mostly completed.

Keep Zim Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.